Kunwar Shailubhai
Corporate Officer/Principal presso Baruch S. Blumberg Institute
Profilo
Founder of Synergy Pharmaceuticals LLC, Kunwar Shailubhai is Professor at Baruch S.
Blumberg Institute.
In his past career Dr. Shailubhai held the position of Executive Director at Rasna Therapeutics, Inc., Chief Executive & Scientific Officer at Tiziana Life Sciences Ltd.
and Executive Director at Tiziana Life Sciences Ltd.
(United Kingdom) (a subsidiary of Tiziana Life Sciences Ltd.), Chief Scientific Officer of Pawfect Foods, Inc., Chief Scientific Officer & Executive VP at Synergy Pharmaceuticals LLC, Vice President-Drug Discovery at Callisto Pharmaceuticals, Inc., Senior Vice President of Drug Discovery Facility and Assistant Professor at the University of Maryland.
He received a doctorate from the University of Baroda and an MBA from the University of Missouri.
Posizioni attive di Kunwar Shailubhai
Società | Posizione | Inizio |
---|---|---|
Baruch S. Blumberg Institute | Corporate Officer/Principal | - |
Precedenti posizioni note di Kunwar Shailubhai
Società | Posizione | Fine |
---|---|---|
TIZIANA LIFE SCIENCES LTD | Chief Executive Officer | 01/08/2022 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - |
ACCUSTEM SCIENCES, INC. | Director/Board Member | 20/06/2022 |
OKYO PHARMA LIMITED | Director/Board Member | 17/06/2021 |
ACTAVIA LIFE SCIENCES, INC. | Chief Executive Officer | 06/02/2020 |
Formazione di Kunwar Shailubhai
University of Missouri | Masters Business Admin |
University of Baroda | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
OKYO PHARMA LIMITED | Health Technology |
ACTAVIA LIFE SCIENCES, INC. | Health Technology |
ACCUSTEM SCIENCES, INC. | Health Technology |
TIZIANA LIFE SCIENCES LTD | Health Technology |
Aziende private | 7 |
---|---|
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Health Technology |
Pawfect Foods, Inc. | Retail Trade |
Active With Me, Inc.
Active With Me, Inc. Miscellaneous Commercial ServicesCommercial Services Active With Me, Inc. provides online resources that seamlessly offer travelers unique, highly relevant and user-friendly information on activity-based travel. Its listings will be provided for product and service providers of interest to the activity-based traveler. The company was founded on December 6, 2012 and is headquartered in Sarnia, Canada. | Commercial Services |
Drug Discovery Facility
Drug Discovery Facility Pharmaceuticals: MajorHealth Technology Part of SCYNEXIS, Inc., Drug Discovery Facility provides research into drug-discovery processes. The private company is based in Cambridge, UK. Drug Discovery Facility was acquired by SCYNEXIS, Inc. from Aventis Cropscience on October 02, 2001. | Health Technology |
Baruch S. Blumberg Institute | |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Health Technology |
Synergy Pharmaceuticals LLC
Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |